tremelimumab astrazeneca
astrazeneca ab - tremelimumab - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)
astrazeneca ab - reasortantni virus gripe (živi oslabljen) s sevom: a / vietnam / 1203/2004 (h5n1) - gripa, človek - cepiva - preprečevanje gripe pri uradno prijavljeni pandemični situaciji pri otrocih in mladostnikih od 12. meseca do starosti manj kot 18 let. pandemije gripe cepiva proti h5n1 astrazeneca je treba uporabljati v skladu z uradnimi smernice.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - carcinom, ikke-småcellet lunge - antineoplastiske midler - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)
astrazeneca ab - reassortant influensavirus (levande dämpad) av följande stam: a / vietnam / 1203/2004 (h5n1) stam - influensa, människa - vacciner - profylax av influensa i en officiellt deklarerad pandemisk situation hos barn och ungdomar från 12 månader till yngre än 18 år. pandemic influenza vaccine h5n1 astrazeneca bör användas i enlighet med officiella riktlinjer.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - karcinom, pljučni pljuč - antineoplastična sredstva - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - rak, niedrobnokomórkowe płuca - Środki przeciwnowotworowe - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - carcinom, non-small cell lung - antineoplastiska medel - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.